股票代码：000538 股票简称：云南白药 公告编号：2026-01 云南白药集团股份有限公司 关于股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于 近日接到公司股东新华都实业集团股份有限公司（以下简称"新华都"） 的通知，获悉新华都将其持有的公司部分股份办理了解除质押。具体情况 如下： 截至本公告披露日，新华都及其一致行动人所持质押股份情况如下： 1 / 3 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押/冻结/拍 卖等股份数 量 占其所 持股份 比例 占公司 总股本 比例 起始日 解除日期 质权人/申请 人等 新 华 都 实 业 集 团 股 份 有 限 公 司 否 75,000,000 17.21% 4.20% 2025-05-09 2026-01-21 兴业银行股 份有限公司 福州分行 合计 / 75,000,000 17.21% 4.20% / / / 一、本次股份解除质押基本情况 | 股东 | | 持股 | 累计质押/ | 占其所 | 占 ...

Core Viewpoint - Yunnan Baiyao announced that its shareholder Xinhua Dou will release the pledge on 75 million shares, which accounts for 17.21% of its holdings and 4.20% of the company's total share capital, starting from May 9, 2025, until January 21, 2026 [1] Summary by Relevant Categories Shareholder Information - Xinhua Dou and its concerted parties hold a total of 449,624,311 shares, representing 25.20% of the company [1] - The total number of pledged shares by Xinhua Dou is 73,500,000, which is 16.35% of its holdings and 4.12% of the company's total share capital [1]

Group 1: Product Development and Clinical Research - The pharmaceutical division is focusing on the secondary development of key products, including clinical studies on Yunnan Baiyao (powder and capsules) for diabetic foot and bone pain, and Gongxue Ning capsules for treating abnormal uterine bleeding [2][3] - Recent clinical research results show Gongxue Ning capsules effectively reduce post-abortion vaginal bleeding and complications, with good overall safety [3] - The Qi Xue Kang oral solution is undergoing multi-center clinical studies for hypertension, with the first patient enrolled successfully [3] Group 2: Business Strategy and Market Expansion - The provincial pharmaceutical company aims to enhance market share in existing hospitals and distribution channels through a "double rise and double drop" strategy, focusing on non-drug businesses and new specialty pharmacies [4] - Efforts will be made to optimize supply chain management and improve accounts receivable and inventory structure, aiming for a patient-centered healthcare ecosystem [4] Group 3: Online Sales Performance - The pharmaceutical division's O2O sales increased by over 20% in the first half of 2025, with significant online marketing efforts boosting product awareness and sales [6] - During the 2025 "618" shopping festival, Yunnan Baiyao toothpaste ranked first in the domestic market share across all channels [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7][8] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, amounting to 1.82 billion CNY, with special dividends accounting for 50.05% of the net profit for that period [8]

Group 1: Online Expansion of Pharmaceutical Business - The pharmaceutical business group has integrated marketing strategies focusing on sports, music, and O2O transaction scenarios, enhancing brand engagement and sales [2] - O2O sales have increased by over 20% year-on-year, supported by online content marketing [2] - The online sales achieved significant results, with e-commerce platforms attracting 48.45 million visitors, generating a GMV of 254 million yuan [3] Group 2: Health Products Sales Performance - The Yangyuanqing hair care products generated sales revenue of 217 million yuan in the first half of 2025, reflecting an 11% year-on-year growth [4] - Yangyuanqing won the "ICIC Technology Innovation Hair Care Product Award" and ranked first in Tmall's domestic anti-hair loss shampoo category during the 2025 "618" shopping festival [4] Group 3: Research and Development Progress - The clinical trials for the product "All Sanqi Tablets" have completed Phase II with 704 participants [5] - The "Fuguben Ointment" has initiated Phase III clinical trials across 15 research centers, enrolling 180 participants [5] - The INR101 diagnostic nuclear medicine project has started Phase III trials with 32 research centers, enrolling 60 participants [5] Group 4: Dividend Distribution - In 2024, the company will distribute a cash dividend of 11.85 yuan per 10 shares, totaling 2.16 billion yuan, which is 90.09% of the net profit attributable to shareholders [6][7] - For the first half of 2025, a cash dividend of 10.19 yuan per 10 shares will be distributed, amounting to 1.82 billion yuan, with special dividends accounting for 50.05% of the net profit for the same period [7]

编号：3-2601-03 云南白药集团股份有限公司 投资者调研会议记录表 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 国泰海通-张澄 东证资管-马庆华 时间 2026 年 1 月 22 日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 22 日星期四 1 / 1 ...

Group 1: Marketing Strategies - The pharmaceutical business unit focuses on becoming the "first brand" in the field of injury and pain management, leading to significant growth in aerosol and plaster products [2] - A comprehensive marketing strategy integrates various scenarios such as sports and music, utilizing platforms like Douyin and Xiaohongshu for broad dissemination [3] - Online sales through O2O channels increased by over 20%, with a total of 48.45 million visitors and 3.54 million consumers generated, resulting in a GMV of 254 million yuan [3] Group 2: R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [4] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with 12 patients enrolled in the Phase I trial [4] Group 3: Health Products Sales - The health products business unit maintains a strong offline presence while increasing investment in online channels, achieving the top market share for toothpaste in China during the first half of 2025 [6] - During the 2025 "618" shopping festival, Yangyuanqing ranked first in Tmall for domestic anti-hair loss shampoo brands [6] Group 4: Development Directions - The company aims for "internal" and "external" collaborative development to optimize its industrial portfolio, focusing on enhancing efficiency in the pharmaceutical, health, and distribution sectors [7] - "Internal" development emphasizes maximizing overall efficiency and high-quality growth across the entire value chain, while "external" development explores strategic mergers and collaborations to overcome growth bottlenecks [7]

投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 国泰海通-张澄 人保资产-黄海培、吴瑞祥、章斌、武丹 时间 2026 年 1 月 22 日 地点 集团总部办公大楼 上市公司接待人员 董事会秘书-钱映辉 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 22 日星期四 编号：2-2601-02 云南白药集团股份有限公司 投资者调研会议记录表 1 / 1 ...

投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 华西医药-程仲瑶 易方达-郭杰、余欣鑫、廖敏华、邓子晗、胡可冕 时间 2026 年 1 月 21 日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 21 日星期三 1 / 1 投资者调研会议记录表 编号：1-2601-01 云南白药集团股份有限公司 ...

证券之星消息，1月23日中药板块较上一交易日上涨0.28%，*ST长药领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出5.1亿元，游资资金净流出5225.91万元，散户资金净流 入5.62亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | 2925.96万 | 3.91% | 124.39万 | 0.17% | -3050.36万 | -4.07% | | 002390 | 信邦制药 | 1707.83万 | 9.03% | -877.49万 | -4.64% | -830.34万 | -4.39% | | 600750 江中药业 | | 1112.58万 | 4.76% | 719.17万 | 3.08% | -- 1831. ...

Core Viewpoint - The report highlights the significant inflow of main capital into various stocks, with specific companies showing remarkable performance in terms of net capital inflow and stock price changes [1][2]. Group 1: Main Capital Inflow - A total of 88 stocks have experienced a net inflow of main capital for five consecutive days or more, indicating strong investor interest [1]. - Hangzhou Bank leads with 16 consecutive days of net inflow, followed by Yunnan Baiyao with 14 days [1]. - Midea Group has the highest total net inflow amounting to 1.582 billion yuan over seven days, while Hangzhou Bank follows closely with 1.489 billion yuan over 16 days [1]. Group 2: Performance Metrics - The stock with the highest net inflow ratio relative to trading volume is Fenglong Co., which has surged by 359.76% over the past 16 days [1]. - Other notable stocks include Guotai Junan Securities with a net inflow of 1.109 billion yuan over 11 days and China Ping An with 1.074 billion yuan over six days, although their stock prices have seen declines of 2.46% and 3.28% respectively [1]. - The report includes a detailed table of stocks with their respective net inflow amounts, inflow ratios, and cumulative price changes, providing a comprehensive overview of market trends [1][2].